

# Ralf Kircheis

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/9509676/ralf-kircheis-publications-by-citations.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

44  
papers

5,506  
citations

24  
h-index

49  
g-index

49  
ext. papers

5,984  
ext. citations

5.7  
avg, IF

5.09  
L-index

#	Paper	IF	Citations
44	PEGylated DNA/transferrin-PEI complexes: reduced interaction with blood components, extended circulation in blood and potential for systemic gene delivery. <i>Gene Therapy</i> , <b>1999</b> , 6, 595-605	4	1084
43	Different behavior of branched and linear polyethylenimine for gene delivery in vitro and in vivo. <i>Journal of Gene Medicine</i> , <b>2001</b> , 3, 362-72	3.5	603
42	Design and gene delivery activity of modified polyethylenimines. <i>Advanced Drug Delivery Reviews</i> , <b>2001</b> , 53, 341-58	18.5	581
41	The size of DNA/transferrin-PEI complexes is an important factor for gene expression in cultured cells. <i>Gene Therapy</i> , <b>1998</b> , 5, 1425-33	4	524
40	Coupling of cell-binding ligands to polyethylenimine for targeted gene delivery. <i>Gene Therapy</i> , <b>1997</b> , 4, 409-18	4	330
39	Polyethylenimine/DNA complexes shielded by transferrin target gene expression to tumors after systemic application. <i>Gene Therapy</i> , <b>2001</b> , 8, 28-40	4	314
38	Novel shielded transferrin-polyethylene glycol-polyethylenimine/DNA complexes for systemic tumor-targeted gene transfer. <i>Bioconjugate Chemistry</i> , <b>2003</b> , 14, 222-31	6.3	272
37	Polycation-based DNA complexes for tumor-targeted gene delivery in vivo. <i>Journal of Gene Medicine</i> , <b>1999</b> , 1, 111-20	3.5	243
36	Tumor-targeted gene therapy: strategies for the preparation of ligand-polyethylene glycol-polyethylenimine/DNA complexes. <i>Journal of Controlled Release</i> , <b>2003</b> , 91, 173-81	11.7	237
35	Different strategies for formation of pegylated EGF-conjugated PEI/DNA complexes for targeted gene delivery. <i>Bioconjugate Chemistry</i> , <b>2001</b> , 12, 529-37	6.3	204
34	Tumor targeting with surface-shielded ligand-polycation DNA complexes. <i>Journal of Controlled Release</i> , <b>2001</b> , 72, 165-70	11.7	129
33	Cancer immunotherapy. <i>Biotechnology Journal</i> , <b>2006</b> , 1, 138-47	5.6	97
32	Specific systemic nonviral gene delivery to human hepatocellular carcinoma xenografts in SCID mice. <i>Hepatology</i> , <b>2002</b> , 36, 1106-14	11.2	91
31	Tumor-targeted gene delivery of tumor necrosis factor-alpha induces tumor necrosis and tumor regression without systemic toxicity. <i>Cancer Gene Therapy</i> , <b>2002</b> , 9, 673-80	5.4	75
30	Analysis of lysine clipping of a humanized Lewis-Y specific IgG antibody and its relation to Fc-mediated effector function. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , <b>2007</b> , 852, 250-6	3.2	69
29	NF- $\kappa$ B Pathway as a Potential Target for Treatment of Critical Stage COVID-19 Patients. <i>Frontiers in Immunology</i> , <b>2020</b> , 11, 598444	8.4	66
28	Compensation of endogenous IgG mediated inhibition of antibody-dependent cellular cytotoxicity by glyco-engineering of therapeutic antibodies. <i>Molecular Immunology</i> , <b>2007</b> , 44, 1815-7	4.3	61

27	Targeted nucleic acid delivery into tumors: new avenues for cancer therapy. <i>Biomedicine and Pharmacotherapy</i> , <b>2004</b> , 58, 152-61	7.5	60
26	Lymphocyte apoptosis: induction by gene transfer techniques. <i>Gene Therapy</i> , <b>1997</b> , 4, 296-302	4	55
25	Tumor-targeted gene delivery: an attractive strategy to use highly active effector molecules in cancer treatment. <i>Gene Therapy</i> , <b>2002</b> , 9, 731-5	4	51
24	Nonviral gene transfer into fetal mouse livers (a comparison between the cationic polymer PEI and naked DNA). <i>Gene Therapy</i> , <b>2003</b> , 10, 810-7	4	46
23	Increase of proliferation rate and enhancement of antitumor cytotoxicity of expanded human CD3+ CD56+ immunologic effector cells by receptor-mediated transfection with the interleukin-7 gene. <i>Gene Therapy</i> , <b>1998</b> , 5, 31-9	4	42
22	Development of transferrin-polycation/DNA based vectors for gene delivery to melanoma cells. <i>Journal of Drug Targeting</i> , <b>1999</b> , 7, 293-303	5.4	34
21	Comparison of the Calibration Standards of Three Commercially Available Multiplex Kits for Human Cytokine Measurement to WHO Standards Reveals Striking Differences. <i>Biomarker Insights</i> , <b>2008</b> , 3, 227-235	3.5	27
20	Correlation of ADCC activity with cytokine release induced by the stably expressed, glyco-engineered humanized Lewis Y-specific monoclonal antibody MB314. <i>MABs</i> , <b>2012</b> , 4, 532-41	6.6	24
19	Inhibition of xenograft tumor growth and down-regulation of ErbB receptors by an antibody directed against Lewis Y antigen. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2006</b> , 319, 1459-66	4.7	24
18	Immunogenicity of therapeutics: a matter of efficacy and safety. <i>Expert Opinion on Drug Discovery</i> , <b>2010</b> , 5, 1067-79	6.2	23
17	Polycation/DNA complexes for in vivo gene delivery. <i>Gene Therapy and Regulation</i> , <b>2000</b> , 1, 95-114		22
16	Antiviral activity of the proteasome inhibitor VL-01 against influenza A viruses. <i>Antiviral Research</i> , <b>2011</b> , 91, 304-13	10.8	21
15	Interleukin-2 gene-modified allogeneic melanoma cell vaccines can induce cross-protection against syngeneic tumors in mice. <i>Cancer Gene Therapy</i> , <b>2000</b> , 7, 870-8	5.4	16
14	Systemic in vivo delivery of siRNA to tumours using combination of polyethyleneimine and transferrin-polyethyleneimine conjugates. <i>Biomaterials Science</i> , <b>2015</b> , 3, 1439-48	7.4	15
13	Functional maturation of dendritic cells by exposure to CD40L transgenic tumor cells, fibroblasts or keratinocytes. <i>Cancer Letters</i> , <b>2001</b> , 168, 145-54	9.9	13
12	SialylTn-mAb17-1A carbohydrate-protein conjugate vaccine: effect of coupling density and presentation of SialylTn. <i>Bioconjugate Chemistry</i> , <b>2005</b> , 16, 1519-28	6.3	10
11	Liposomes as cytokine-supplement in tumor cell-based vaccines. <i>International Journal of Pharmaceutics</i> , <b>1999</b> , 183, 33-6	6.5	10
10	Coagulopathies after Vaccination against SARS-CoV-2 May Be Derived from a Combined Effect of SARS-CoV-2 Spike Protein and Adenovirus Vector-Triggered Signaling Pathways. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	7

9	Immunization of Rhesus monkeys with a SialylTn-mAb17-1A conjugate vaccine co-formulated with QS-21 induces a temporary systemic cytokine release and NK cytotoxicity against tumor cells. <i>Cancer Immunology, Immunotherapy</i> , <b>2007</b> , 56, 863-73	7.4	6
8	Immunization of Rhesus monkeys with the conjugate vaccine IGN402 induces an IgG immune response against carbohydrate and protein antigens, and cancer cells. <i>Vaccine</i> , <b>2006</b> , 24, 2349-57	4.1	4
7	Xenogenization by tetanus toxoid loading into lymphoblastoid cell lines and primary human tumor cells mediated by polycations and liposomes. <i>Cancer Letters</i> , <b>2000</b> , 161, 241-50	9.9	4
6	Phase I Dose Escalation Study with the Lewis Y Carbohydrate Specific Humanized Antibody IGN311. <i>Journal of Cancer Therapy</i> , <b>2011</b> , 02, 760-771	0.2	3
5	COVID-19: Mechanistic Model of the African Paradox Supports the Central Role of the NF- $\kappa$ B Pathway. <i>Viruses</i> , <b>2021</b> , 13,	6.2	2
4	Could a Lower Toll-like Receptor (TLR) and NF- $\kappa$ B Activation Due to a Changed Charge Distribution in the Spike Protein Be the Reason for the Lower Pathogenicity of Omicron?. <i>International Journal of Molecular Sciences</i> , <b>2022</b> , 23, 5966	6.3	2
3	In Response to: Smpact of Glycosylation on Effector Functions of Therapeutic IgGS(Pharmaceuticals 2010, 3, 146-157). <i>Pharmaceuticals</i> , <b>2010</b> , 3, 1887-1891	5.2	1
2	Safety and Therapeutic Efficacy of the Lewis Y Carbohydrate Specific Humanized Antibody MB311 in Patients with Malignant Effusion. <i>Journal of Cancer Therapy</i> , <b>2014</b> , 05, 28-37	0.2	1
1	Induction of Human Anti-Human Antibody Responses (Ab2) after Application of a Humanized Lewis Y Carbohydrate Specific Antibody (Ab1): Connection of Prolonged Disease Stabilization with Ab3 Induction?. <i>Journal of Cancer Therapy</i> , <b>2012</b> , 03, 269-277	0.2	1